MedWatch

Lundbeck closes RNA deal worth USD 109m with US biotech firm

Danish pharmaceutical firm Lundbeck enters a strategic collaboration with US biotech group Rgenta in order to find small molecules targeting RNA and develop new treatments for neurological diseases. To start with, the Danish company pays DKK 63m, and in time, it might end up paying DKK 628m in milestone payments.

Lundbeck Vice President Klaus Bæk Simonsen | Photo: Lundbeck / PR

New treatments for rare brain diseases in a potentially very lucrative market.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs